Literature DB >> 15175894

Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.

Francesco Passamonti1, Elisa Rumi, Lucia Malabarba, Luca Arcaini, Ester Orlandi, Ercole Brusamolino, Cristiana Pascutto, Mario Cazzola, Mario Lazzarino.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15175894     DOI: 10.1007/s00277-004-0882-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  6 in total

1.  Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients.

Authors:  Francesca Palandri; Nicola Polverelli; Emanuela Ottaviani; Fausto Castagnetti; Michele Baccarani; Nicola Vianelli
Journal:  Haematologica       Date:  2010-01-15       Impact factor: 9.941

2.  Pipobroman gets regulatory approval outside Germany.

Authors:  Antonis G Tsamaloukas
Journal:  Dtsch Arztebl Int       Date:  2008-01-25       Impact factor: 5.594

3.  How I treat essential thrombocythemia.

Authors:  Philip A Beer; Wendy N Erber; Peter J Campbell; Anthony R Green
Journal:  Blood       Date:  2010-11-24       Impact factor: 22.113

Review 4.  Essential thrombocythemia.

Authors:  Jean B Brière
Journal:  Orphanet J Rare Dis       Date:  2007-01-08       Impact factor: 4.123

Review 5.  Essential thrombocythemia treatment algorithm 2018.

Authors:  Ayalew Tefferi; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Blood Cancer J       Date:  2018-01-10       Impact factor: 11.037

6.  Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.

Authors:  A Tefferi; O Abdel-Wahab; F Cervantes; J D Crispino; G Finazzi; F Girodon; H Gisslinger; J Gotlib; J-J Kiladjian; R L Levine; J D Licht; A Mullally; O Odenike; A Pardanani; R T Silver; E Solary; T Mughal
Journal:  Blood Cancer J       Date:  2011-03-04       Impact factor: 11.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.